Lexeo Therapeutics, Inc.
LXEO Nasdaq
SEC CIK 1907108
Follow Lexeo Therapeutics
Weekly email: filings, results
Net income
−$38.3M
−88.8% vs same quarter last year
EPS, diluted
−$0.43
−30.3% vs same quarter last year
Operating cash flow
−$28.6M
+3.3% vs same quarter last year
Operating income
−$40.4M
−86.6% vs same quarter last year
Source: SEC XBRL filings · latest filing
Show the numbers
| Year | Net income |
|---|---|
| FY25 | −$100M |
| FY24 | −$98.3M |
| FY23 | −$66.4M |
| FY22 | −$59.3M |
| FY21 | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$99M |
| FY24 | −$81.6M |
| FY23 | −$59.6M |
| FY22 | −$55.2M |
| FY21 | - |